含HCPT方案联合放疗治疗晚期食管癌的临床研究

将 69例晚期食管癌患者分为 2组 :研究组 3 1例 ,应用HCPT联合PF方案化疗与放疗结合 ;对照组 3 8例 ,除化疗方案中不加HCPT外 ,其余治疗与对照组相同。原发灶和转移灶两组疗效差异均有统计学意义 ,P <0 0 5。常见的毒副反应 :骨髓抑制发生率为 77 4% ( 2 4/3 1) ;胃肠道反应发生率为 64 5 % ( 2 0 /3 1) ;神经毒性发生率为 45 2 % ( 14 /3 1)。初步研究结果提示 ,含HCPT方案联合放疗治疗晚期食管癌近期疗效良好 ,毒副反应可耐受 ,值得推广。

Clinical reseach of hydroxycamptothecin combined chemotherapy with radiotherapy in advanced esophageal cancer

OBJECTIVE:Sixty-nine advanced esophageal cancer patients were divided into two groups. The study group had 31 cases, treated with hydroxycamptothecin (HCTP) combined chemotherapy with radiotherapy. The control group had 38 cases, treated with PF regimen. The difference between the two groups both the primary disease and the matastasis was statistically significant, P<0.05. The common side-effects were arrest of bone marrow (77.4%, 24/31),digestive tract reaction (64.5%, 20/31) and neurotoxicity (45.2%, 14/31), and there was no statistical significance between the two groups, P>0.05. In conclusion, HCTP combined chemotherapy with radiotherapy is effective for advanced esophageal cancer. The side-effect was mild. Therefore, it is warranted for wide use.